DAFTAR PUSTAKA

1. Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia:
contemporary concerns. Semin Hematol. 2016;53:35–9.
2. Astermark J, Donfield SM, Gomperts ED, Schwarz J, Menius ED, Pavlova A,
Oldenburg J, Kessing B, DiMichele DM, Shapiro AD, Winkler CA, Berntorp
E, et al. The polygenic nature of inhibitors in hemophilia A: results from the
Hemophilia Inhibitor Genetics Study (HIGS) Combined
Cohort. Blood. 2013;121:1446–54.
3. Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M.,
Paediatric Working Party of the United Kingdom Haemophilia Doctors’
Organization. Guideline on the management of haemophilia in the fetus and
neonate. Br J Haematol. 2011;154:208–15.
4. Fogarty PF, Kessler CM. Hemophilia A and B. In: Kitchens CS, Kessler CM,
Konkle BA, eds. Consultative Hemostasis and Thrombosis. 3 ed. Philadelphia,
PA: Elsevier Saunders; 2013:45-59.
5. Josephson N. The hemophilias and their clinical management. Hematology Am
Soc Hematol Educ Program. 2013;2013:261-7.
6. Kaufman RJ, Fay PJ, Popolo L, Ortel TL. Factor V and factor VIII. In: Marder
VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. Hemostasis and
Thrombosis: Basic Principles and Clinical Practice. 6 ed. Philadelphia, PA:
Lippincott Williams and Wilkins; 2013:179-96.
7. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors
for hemophilia. Hematology Am Soc Hematol Educ Program. 2013;2013:30-
6.
8. Myrin-Westesson L, Baghaei F, Friberg F. The experience of being a female
carrier of haemophilia and the mother of a haemophilic
child. Haemophilia. 2013;19:219–24. doi: 10.1111/hae.12026. PubMed
PMID: 23006036.
9. Dunn AL. Pathophysiology, diagnosis and prevention of arthropathy in patients
with haemophilia.Haemophilia. 2011;17:571–8. doi: 10.1111/j.1365-
2516.2010.02472.x. PubMed PMID: 21342365.
10. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and
management of haemophilia. BMJ 2012; 344: e2707.
11. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J.
Harrison`s principles of internal medicine. New York: McGraw Hill; 2015.
12. Astermark J, Donfield SM, Gomperts ED, Schwarz J, Menius ED, Pavlova A,
Oldenburg J, Kessing B, DiMichele DM, Shapiro AD, Winkler CA, Berntorp
E, et al. The polygenic nature of inhibitors in hemophilia A: results from the
Hemophilia Inhibitor Genetics Study (HIGS) Combined
Cohort. Blood. 2013;121:1446–54.
13. Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia:
contemporary concerns. Semin Hematol. 2016;53:35–9.
14. Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG,
Margaglione M, Thrompson AR, van Heerde W, Boekhorst J, Miller CH, le
Cessie S, van der Bom JG. F8 gene mutation type and inhibitor development
in patients with severe hemophilia A: systemic review and meta-
analysis. Blood. 2012;119:2922–34.
15. Hay CR, Palmer B, Chalmers E, Liesner R, Maclean R, Rangarajan S, Williams
M, Collins PW. Incidence of factor VIII inhibitors throughout life in severe
hemophilia A in the United Kingdom. Blood. 2011;117:6367–70.
16. Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris
M, Riker E, Santesso N, Soucie JM, Yeung CHT, Iorio A, Schünemann HJ.
NHF-McMaster guideline on care models for haemophilia
management. Haemophilia. 2016;22 Suppl 3:6–16.
17. Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S,
Gercheva L, Rusen L, Ghinea M, Uscatescu V, Rescia V, Hong W.
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-
demand treatment with sucrose-formulated recombinant factor VIII in adults
with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119–27.
18. Mondorf W, Kalnins W, Klamroth R. Patient-reported outcomes of 182 adults
with severe haemophilia in Germany comparing prophylactic vs. on-demand
replacement therapy. Haemophilia. 2013;19:558–63.
19. Stemberger M, Kallenbach F, Schmit E, McEneny-King A, Germini F, Yeung
CHT, Edginton AN, von Mackensen S, Kurnik K, Iorio A. Impact of Adopting
Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A
Patients: A Historically Controlled Observational Study. Thromb.
Haemost. 2019 Mar;119(3):368-376.
20. Spencer HT, Riley BE, Doering CB. State of the art: gene therapy in
haemophilia. Haemophilia. 2016;22 Suppl 5:66–71.
21. Funnell APW, Crossley M. Hemophilia B Leyden and once mysterious cis-
regulatory mutations. Trends Genet. 2014;30:18–23.
22. Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J
Thromb Haemost. 2015;13:1184–95.
23. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia:
diagnosis, treatments, and its complications. Lancet. 2016;388:187–97.

Stemberger M, Kallenbach F, Schmit E, McEneny-King A, Germini F,

Yeung CHT, Edginton AN, von Mackensen S, Kurnik K, Iorio A. Impact
of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in
Haemophilia A Patients: A Historically Controlled Observational
Study. Thromb. Haemost. 2019 Mar;119(3):368-376. [PubMed]
2.
Morfini M, Rapisarda CAP. Safety of recombinant coagulation factors in
treating hemophilia. Expert Opin Drug Saf. 2019 Feb;18(2):75-
85. [PubMed]
Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb
Hemost. 2013;39:621–31.